AXIS 2: AX200 for the Treatment of Ischemic Stroke - A Multinational, Multicenter, Randomized, Doubleblind, Placebo-Controlled Phase II Trial.

Trial Profile

AXIS 2: AX200 for the Treatment of Ischemic Stroke - A Multinational, Multicenter, Randomized, Doubleblind, Placebo-Controlled Phase II Trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms AXIS-2
  • Sponsors SYGNIS Bioscience GmbH
  • Most Recent Events

    • 14 Apr 2012 Planned number of patients changed from 328 to 350 as reported by European Clinical Trials Database.
    • 14 Feb 2012 Due to the results from this trial, clinical development of AX 200 for the treatment of acute stroke was ceased, according to a Sygnis Pharma media release.
    • 15 Dec 2011 Primary endpoint 'Rankin-scale' has not been met, according to a Sygnis Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top